Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Multi-Center Study to Evaluate the Efficacy and Safety of Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

NCT04994626 is registered in ClinicalTrials.gov with Chinese Academy of Medical Sciences as lead sponsor.

NCT NCT04994626
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04994626 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Multi-Center Study to Evaluate the Efficacy and Safety of Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies
Lead sponsor
Chinese Academy of Medical Sciences
Phase
Phase 2
Overall status
Unknown status
Start date
October 1, 2021
Completion date
July 1, 2025
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cd79a gene mutation, cd79b gene mutation, dlbcl, myd88 gene mutation, refractory lymphoma, relapse